Monopar Therapeutics
Manufacturing · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1000 Skokie Blvd Ste 350, Wilmette, Illi...Phone Number
(847) 388-0349Website
www.monopartx.comRevenue
$7.5 MillionStock Symbol
MNPRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Monopar Therapeutics
Monopar Therapeutics is a biopharmaceutical company founded in 2014 that specializes in developing orphan oncology compounds for the treatment of rare cancers. The company focuses on innovative therapeutic approaches, including monoclonal antibodies that target specific cancer pathways. Monopar Therapeutics works on developing treatments for several deadly cancers through specialized pharmaceutical research and clinical trials. With operations in both San Francisco, California and Chicago, Illinois, the company collaborates with international research organizations to advance its pharmaceutical development pipeline. Monopar Therapeutics maintains a focus on addressing unmet medical needs in oncology through its specialized pharmaceutical manufacturing and development processes.Explore more
Monopar Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
JH
Director, Supply Chain Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Monopar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Monopar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Monopar Therapeutics
Website visits: Recent activity has been detected on your website
Check if Monopar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Monopar Therapeutics recently announced quarterly report
Product Launch: Get notified when Monopar Therapeutics launches new products
Check out if Monopar Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Monopar Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Monopar Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Monopar Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Monopar Therapeutics
Compare insights from companies similar to Monopar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Monopar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Monopar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Monopar Therapeutics.
Monopar Therapeutics financials insights
Gather financial insights about Monopar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$2.1M
Monopar Therapeutics Tech Stack
A closer look at the technologies used by Monopar Therapeutics
Most Recent Scoops
Person-Based
Project
, according to a mid-level source in operations management, is planning to begin initiatives related to enterprise resource planning (ERP) software within three months. The organization is currently evaluating Oracle E-Business Suite, SAP Business One, and SAP ERP.
Enterprise Software, Software, Enterprise Resource Planning, Operations
Project
, according to a mid-level source in operations management, has completed initiatives related to artificial intelligence and machine learning within the last twelve months.
Machine Learning, Artificial Intelligence, Operations
Project
, according to a mid-level source in operations management, is planning to begin initiatives related to environmental, quality and safety management software within three to six months. These efforts are focused on cleanroom safety, sterility, and quality.
Software, Safety, Health & Safety, Operations
Project
Artificial Intelligence, Operations
Monopar Therapeutics News & Media
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company’s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval. Nicole Sweeny, former Chief Commercial Officer of KalVistaMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company’s late-stage candidate for the treatment of Wilson disease.Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland.Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation (link) of Phase 2 ALXN1840-WD-205 data at the European Association for the Study of the Liver (EASL) Congress 2026. In a presentation titled “ALXN1840 (tiomolibdate choline) Stabilizes Liver Disease and Improves Neurological Sympto
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Monopar Therapeutics
Sign Up For FreeTo access detailed company insights
Monopar Therapeutics is a biopharmaceutical company founded in 2014 that specializes in developing orphan oncology compounds for the treatment of rare cancers. The company focuses on innovative therapeutic approaches, including monoclonal antibodies that target specific cancer pathways. Monopar Therapeutics works on developing treatments for severa... Read More
